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SUMMARY

Author Manuscript

Melanomas accumulate a high burden of mutations that could potentially generate neoantigens,
yet somehow suppress the immune response to facilitate continued growth. In this study, we
identify a subset of human melanomas that have loss of function mutations in ATR, a kinase that
recognizes and repairs UV-induced DNA damage and is required for cellular proliferation. ATR
mutant tumors exhibit both the accumulation of multiple mutations and the altered expression of
inflammatory genes, resulting in decreased T-cell recruitment and increased recruitment of
macrophages known to spur tumor invasion. Taken together, these studies identify a mechanism by
which melanoma cells modulate the immune microenvironment to promote continued growth.
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Tumors grow not only because they acquire mutations that promote their growth, but also because
they prevent the immune system from recognizing them. Chen et al. identify ATR mutations in
human melanoma tumors and determine that ATR mutant melanomas harness the immune system
to accelerate tumor growth.

Author Manuscript
INTRODUCTION

Author Manuscript

Melanomas accumulate a high burden of UV-induced mutations (Hodis et al., 2012). While
genomic studies have identified some putative melanoma driver mutations, leading to the
development of agents such as MAP kinase inhibitors that induce tumor regression
(Wellbrock and Arozarena, 2016), it is less understood how other UV-induced mutations and
tumor heterogeneity as a whole modulates tumor growth. These questions are not easily
addressed by existing in vivo models, as existing animal models are either genetically
homogeneous or lack a functional immune system (Kuzu et al., 2015).

Author Manuscript

While UV-irradiation contributes to the high mutation burden in skin cancer (Martincorena
et al., 2015), melanoma tumors accumulate even more mutations as they fail to repair UVdamaged DNA. Patients with the DNA repair disorder Xeroderma Pigmentosum have an
increased risk of melanoma (Masaki et al., 2014), while mutations that affect telomere
maintenance are also linked to melanoma (Potrony et al., 2015), and mutations in CDKN2a,
which is commonly defective in melanoma (Hayward, 2003), also regulates genome
maintenance (Box and Terzian, 2008). Melanoma cells also have DNA damage checkpoint
defects-70% of cutaneous melanoma cell lines demonstrate defective G1 checkpoint arrest
(Carson et al., 2012). Finally, some patients predisposed to melanoma have mutations in the
MC1R receptor which is known to activate DNA repair mechanisms (Cassidy et al., 2015)
by modulating the activity of the ATR kinase (Jarrett et al., 2015; Jarrett et al., 2014).
The ATR kinase is essential for the viability of both human and mouse cells (Brown and
Baltimore, 2000; Cortez et al., 2001). In response to single stranded DNA damage, the ATR
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kinase is recruited to damaged DNA, becomes activated, and then phosphorylates its
downstream target Chk1 (Cimprich and Cortez, 2008). Activation of Chk1 results in cell
cycle arrest and DNA repair to prevent damaged cells from progressing through the cell
cycle (Smits and Gillespie, 2015). Chk1 is essential for the development of murine
melanocytes (Smith et al., 2013), identifying a specific role for ATR-Chk1 in the melanocyte
lineage. While ATR is essential for replication, hypomorphic mutations in ATR are observed
in Seckel syndrome (O’Driscoll et al., 2003), a recessive disorder characterized by
developmental delay and premature aging. Similarly, ATR mutant (ATR mt) mice develop
signs of premature aging and hair greying (Ruzankina et al., 2007). Partial loss-of-function
ATR mutations also can cause an oropharyngeal cancer syndrome (Tanaka et al., 2012).

Author Manuscript

In this study, we sought to examine whether ATR mutations can contribute to the
development of melanoma. We identify ATR loss of function mutations in human
melanoma, and determine that introducing similar mutations into BRAF mt PTEN
heterozygous mouse melanomas (Dankort et al., 2009) accelerates both tumor growth and
mutation accumulation. ATR mt tumors in this model recruited proinflammatory
macrophages while repelling T cells important for the anti-tumor response, identifying ATR
mutations that modulate the immune response to promote growth.

RESULTS
Loss of Function ATR mutations are present in human melanoma

Author Manuscript

Initial studies identified mutations in the ATR pathway in human melanoma. 7% of
melanoma tumors in the TCGA have mutations in genes that affect the ATR pathway (ATR
and CHK1), with most of these mutations occurring in the ATR gene (6%) (Supplemental
Data File1-sheet1). Analysis of an independent set of primary tumors revealed a higher
incidence of ATR mutations (13%, Supplemental Data File1-sheet1). ATR mutations did not
map to a specific hotspot within the open reading frame (Figure S1A, Supplemental Data
File1-sheet2), and none of the ATR mutations observed were recurrent in the dataset
analyzed. ATR mt tumor cell lines from this cohort were examined to determine whether
they had defective cell cycle checkpoints. Upon UVB-irradiation, ATR is recruited to
damaged DNA and initiates the phosphorylation of CHK1 at Serine 345, initiating cell cycle
arrest (Marechal and Zou, 2013). While UVB-irradiation was sufficient to induce CHK1
phosphorylation in ATR-WT melanomas (WM983B, A375, MNT1, WM3211, WM3428)
(Figure1A, left panel and Figure S1B), it did not induce the accumulation of phospho-CHK1
in ATR mt melanoma cell lines (JWCI-WGS18, JWCI-WGS22, MeWo, MB435S) as
efficiently with the exception of JWCI-WGS01 and JWCI-WGS31 (Figure 1A).

Author Manuscript

To assess whether ATR mt melanoma cell lines had defective cell cycle checkpoints, we
examined whether UVB-irradiation induced cell cycle arrest in ATR WT (WM983B, A375)
or mt melanomas. We excluded MNT-1 cells from this analysis as melanin in these cells
interfered with the EdU assay. ATR mt cell lines incorporated less EdU after 1 hr of labeling
as compared to ATR WT cells (Figure 1B) whether or not they exhibited defects in Chk1
phosphorylation, suggesting that all of these mts have some defects in the activation of ATR
downstream targets. UVB-irradiation induced cell cycle arrest in ATR WT cells (A375), as
similar percentages of EdU positive cells were observed in samples labeled for 1 hour
Cell Rep. Author manuscript; available in PMC 2018 March 07.
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followed by a 6 hr post UV chase as was observed in control cells labeled for 1 hr (Figure
1C, S1C). Several ATR-mt cell lines (JWCI-WGS18, MeWo, MB435S) had defects in UVinduced cell cycle arrest, as cells were able to proliferate after UV-irradiation, diluting out
the population of cells that were labeled with EdU during the first hour (Figure 1B, S1C).
The ability to overcome this replication block (Figure 1C) correlated with the magnitude of
defects in UVB-induced Chk1 phosphorylation (Figure 1A). Taken together, these studies
verify that subsets of melanoma tumors have ATR loss of function mutations.

Author Manuscript

Next, we verified that the ATR mutants in MB435S, MeWo, and JWCI-WGS18 cell lines,
which exhibited altered UVB-induced checkpoints, interfered with the function of WT ATR.
ATR mt constructs were generated and expressed at low levels in an A375 melanoma cell
line that also express WT ATR. Initial studies verified that each WT or mt Flag-tagged ATR
construct was expressed at a low level in A375 cells, and that these cell lines expressed
similar levels of total ATR (Figure 1D, left panel). While UVB-irradiation induced Chk1
phosphorylation in cells that express WT ATR, UVB-irradiation was less efficient at
inducing Chk1 phosphorylation in cells that express a kinase dead ATR mt (Figure 1D,
D2475A) (Nghiem et al., 2001) or in cells that express the ATR mts that had defective DNA
damage checkpoints as identified in Figure 1A and 1C (Figure 1D, right panel). These
findings verify that the heterozygous ATR mutations observed in human tumors have
functional consequences.
ATR mutations accelerate the growth and metastasis of melanomas in vivo

Author Manuscript

In order to determine whether ATR mutations contribute to tumor development and
metastasis in vivo, we crossed Atrflox/flox mice in which the loxP sites flank the ATR kinase
domain (Brown and Baltimore, 2003) (Figure 2A, 2B upper panel) with mice carrying a
Tyrosinase::CreERT2 allele, a BrafCA allele, and zero, one or two copies of a Ptenlox4-5 allele
(Dankort et al., 2009). The growth of nevi or tumors in this model could be modulated by
altering the dosage of PTEN: melanocytes expressing mt BRAF and WT PTEN produce
nevi but no melanoma, melanocytes expressing mt BRAF and one copy of PTEN form
tumors that are visible after >75 days, while melanocytes that express mt BRAF and no
PTEN rapidly develop melanomas that metastasize quickly (Dankort et al., 2009). Initial
studies verified that: 1) mice containing BRAF mt melanocytes had a normal lifespan and
didn’t develop tumors (Figure S2A); and 2) tumor development was influenced by the
absence of one PTEN allele but not by ATR mt (Figure S2B).

Author Manuscript

In this set of experiments, we examined the consequences of ATR loss in nevi and
melanoma using a published ATR flox model in which the excision of the ATR flox cassette
is not 100% complete (Ruzankina et al., 2007), resulting in the generation of mice that have
some melanocytes with no functional ATR and others with WT ATR. Over time, a mixed
population of ATR−/− and ATR+/+ cells can then repopulate tissues of these animals. While
this feature makes it difficult to measure the effect of complete ATR loss on tumor growth, it
does generate tumors that have a mixture of different mutations as is observed in human
melanoma. Induction of recombination with topical 4-OHT in these mice would result in the
simultaneous BRAFV600E mutation, generation of some cells with mixed deletion of the
ATR kinase domain (termed ATRmD), and PTEN deletion specifically in melanocytes
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(Figure 2A). The ATR protein is very large (300 kDa), yet the kinase domain of the protein
is very small, making it impossible to distinguish truncated ATR from full length ATR by
western blotting (Figure S2C). RT-PCR (reverse transcriptase PCR) of tumor RNA
successfully demonstrated that ATR mD (mD/mD) tumors contained the truncated ATR
transcript of the appropriate size (Figure 2B, bottom left panel) while also containing the
WT transcript. Additional studies verified that mRNA corresponding to the floxed form of
ATR was expressed in melanoma tumors (Figure 2B, bottom right panel). In order to verify
that ATR mt melanomas had defects in cell cycle checkpoints, ATRmD/mD and ATR+/+
tumors were lysed, and subjected to western blotting with p-Chk1(S345) Ab. ATRmD/mD
tumor cells exhibited decreased phosphorylation of CHK1 (Figure 2C), indicating that these
tumors lacked normal cell cycle checkpoints. ATRmD/mD tumors also had less expression of
ATR but no change in the expression of ATM (Figure 2C) even though the ATR flox allele
migrates at the same size of the WT allele (Figure S2C). Taken together, these findings
verify that the ATRmD/mD tumors had ATR singaling defects.

Author Manuscript

To examine whether ATR signaling influenced tumor progression, Tyrosinase::CreERT2;
BrafCA/+; Ptenfl/+; Atrfl/+ or Atrfl/fl mice were generated and tumor formation was induced
by topical administration of 4-OHT. PTEN+/− tumors were specifically selected for these
experiments as these tumors develop more slowly, making it easier to identify an effect of
ATR on tumor growth. BRAFV600E PTEN+/− ATRmD/+ tumors grew larger than BRAFV600E
PTEN+/− ATR+/+ tumors (Figure 2D), ultimately resulting in the tumor growing so large that
these mice had to be sacrificed prematurely for compassionate reasons (Figure 2E) (decrease
in median survival of 14 days). While BRAFV600E PTEN+/− ATRmD/mD tumors grew to a
larger size than ATR WT tumors (Figure 2D), the BRAFV600E PTEN+/− ATRmD/mD tumors
did not reach a sufficient size that mice needed to be sacrificed sooner than mice carrying
BRAFV600E PTEN+/− ATRmD/+ tumors (Figure 2E). These observations are consistent with
other studies that have indicated that ATR can have differing effects on tumor growth
dependent on gene dosage (Gilad et al., 2010).
Deletion of both copies of PTEN in mouse melanomas rapidly accelerates their growth,
resulting in a high tumor burden that goes on to generate lung metastases (Dankort et al.,
2009). Deletion of one or both copies of the ATR kinase domain in BRAFV600E PTEN null
melanocytes did not result in an increased burden of tumors (Figure 2F), consistent with the
published observation that BRAFV600E PTEN null tumors develop and metastasize rapidly.
BRAFV600E PTEN−/− ATRmD/mD tumors did, however, have a higher propensity to
metastasize to the lung as compared to BRAFV600E PTEN−/− tumors (Figure 2G, S2D).
Taken together, these studies suggest that ATR mutations influence both the growth and
metastasis of BRAF mt melanomas.

Author Manuscript

ATR mt promote the growth of BRAF mt nevi
As ATR mts modulate both tumor growth and metastasis, we next sought to examine the role
of ATR mt in the growth of nascent tumors and nevi. First, we examined mice 75 days after
birth when tumors are first readily visible. Both BRAFV600E PTEN+/− ATRmD/+ tumors and
BRAFV600E PTEN+/− ATRmD/mD tumors (Figure 3A) were larger in size as compared to
BRAFV600E PTEN+/− ATR+/+ tumors after 75 days. Moreover, a greater number of tumors
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were observed per mouse in mice carrying ATRmD/+ tumors and ATRmD/mD tumors (Figure
3A) when compared to ATR+/+ tumors. Tyrosinase::CreERT2;BrafCA/+ mice develop
melanocytic nevi after 4-OHT administration that can progress to melanoma after a
prolonged duration (Dhomen et al., 2009). To more accurately assess whether ATR
deficiency affects tumor initiation, we generated Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice
and induced precancerous nevi formation using topical 4-OHT treatment. Initial experiments
verified that Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl and Tyrosinase::CreERT2; BrafCA/+ mice
had no difference in overall survival, and validated that these mice had similar survival as
WT mice as noted in earlier publications (Dankort et al., 2009) (Figure S2A, S2B). The
number of nevi after tamoxifen topical administration in Tyrosinase::CreERT2; BrafCA/+
Atrfl/fl and Tyrosinase::CreERT2; BrafCA/+ mice was quantified visually and using
multiphoton microscopy (MPM), a technique that utilizes only intrinsic fluorescent signals
to generate a three-dimensional image of melanoma tumors (Balu et al., 2014).
Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice develop more nevi after 4-OHT treatment
compared to Tyrosinase::CreERT2; BrafCA/+ mice (Figure 3B). By measuring the intrinsic
fluorescent signals from melanin (red), keratin (green), and the second harmonic signals
from collagen (blue) using MPM (Balu et al., 2014) (Figure 3C, Supplemental video 1–3),
we were able to determine that the developing ATR mt nevi were larger in volume (Figure
3D) and occupied a larger volume of the skin (Figure 3E). There were also a larger number
of nevi in Tyrosinase::CreERT2; BrafCA/+ Atrfl/fl mice although this number was just below
statistical significance (p=0.0503) (Figure 3F). Taken together, these studies indicated that
ATR deficiency affects tumor initiation.
ATR mt Melanomas Accumulate More Mutations

Author Manuscript
Author Manuscript

To investigate how ATR mutations affected mutation accumulation, the genomes of
BRAFV600E PTEN+/− ATRmD/mD and BRAFV600E PTEN+/− ATR+/+ mouse tumors were
sequenced and compared. Initial studies identified single nucleotide variants (SNVs) present
in BRAFV600E PTEN+/− ATRmD/mD and BRAFV600E PTEN+/− ATR+/+ tumors and
determined that ATR mt tumors accumulated more SNVs (Supplemental data file 1-sheet 4
and sheet 5). Comparison of the number of SNVs in these two tumors revealed that ATR mt
tumors accumulated more single nucleotide variants (Figure 4A). ATR SNVs had no
predilection for specific transitions or transversions (Figure 4B), and were randomly
dispersed across the genome, including both coding and regulatory regions (Figure 4C). In
contrast, there was not a drastic increase in the number of translocations in ATRmD/mD
tumors (two inversions and one area of LOH was observed, data not shown), suggesting that
the ATR mutation was not a complete loss of function, as has been described by others
(Ruzankina et al., 2007), as it resulted in the accumulation of SNVs and not translocations as
observed in ATR null cells (Chanoux et al., 2009). In addition, while ATR mt tumors
accumulated more SNVs in chromosome 7 and 12 (Figure 4A), these SNVs were evenly
distributed across the chromosome and did not localize to any particular hotspot (Figure S3),
indicating that the altered growth properties of these tumors was unlikely to be driven by a
specific mutation induced by ATR loss.

Cell Rep. Author manuscript; available in PMC 2018 March 07.

Chen et al.

Page 7

Author Manuscript

ATR mt Tumors Generate a Pro-Inflammatory Microenvironment that Supports Tumor
Growth

Author Manuscript

Initial studies revealed that ATR mt melanoma cells do not proliferate more rapidly, as the
number of Ki67 positive cells in ATR WT and mt tumors was similar (data not shown),
consistent with published studies indicating that ATR function is required for cellular
replication (Brown and Baltimore, 2003). In order to better understand how ATR deletion
promotes the growth of tumors as a whole, RNA was collected from BRAFV600E ATRmD/mD
nevi and BRAFV600E ATR+/+ nevi and subjected to RNA-seq and differential expression
analysis (Figure S4A, Supplemental data file 1-sheet 6). ATR mt nevi had decreased
expression of jun and fos (Figure 5A), serum response factors whose expression positively
correlates with cellular proliferation (Verde et al., 2007), indicating that these tumors were
not more proliferative (Figure S4A). Notably, ATR mt nevi had decreased expression of
SkinT genes (Figure 5A), a class of genes known as butyrophilins (Abeler-Dorner et al.,
2012) that promote T cell homing to epithelia (Barbee et al., 2011). ATR mt nevi also had
decreased expression of CD4, a marker for T-cells and other immune cells (Figure 5A),
indicating that ATR tumors downregulate T-cell homing mechanisms. Taken together, these
studies suggested that ATR mt tumors do not proliferate more rapidly but instead promote
tumor growth by modulating the immune response.

Author Manuscript

To better characterize the effect of ATR mt on the immune response, flow cytometry was
utilized to quantify the number of infiltrating immune cells in ATR mt and ATR WT tumors.
ATRmD/mD melanoma tumors had decreased numbers of infiltrating T-cells (CD3+, pan T
cell marker) and increased numbers of infiltrating macrophages (F4/80+) and B cells (CD19,
B cell marker) as compared to ATRmD/+ and ATR+/+ tumors (Figure 5B). Interestingly, 40%
of the cells in ATRmD tumors were macrophages. Consistent with this observation, RNA-seq
analysis of BRAFV600E PTEN+/− ATRmD/mD tumors and BRAFV600E PTEN+/− ATR+/+
tumors did indicate that genes involved in immune activation were preferentially expressed
in ATR mt tumors (Figure S5A, S5B, Supplemental data file 1-sheet 7).
Immunohistochemical studies revealed that ATR mt tumors had increased numbers of
infiltrating macrophages (Figure S4B) and decreased number of infiltrating T cells (Figure
S4C), further verifying the flow cytometry results. Unfortunately, it was difficult to measure
an effect on B cells histologically, as very few infiltrating B cells were present in either
specimen (Figure S4D).

Author Manuscript

Blood monocytes extravagate into target tissues where they differentiate into mature
macrophages and polarize into diverse subsets depending on environmental challenge
(Murray and Wynn, 2011). While macrophage polarization is exceedingly complex,
simplified in vitro models suggest that macrophages can polarize into “M1” subsets which
are involved in generating an anti-tumor immune response or “M2” polarized subsets which
can exert anti-inflammatory and pro-tumorigenic properties (Galdiero et al., 2013).
Macrophages are detected in genetically heterogeneous tumors (Bauer et al., 2011) and can
promote melanoma invasion and metastasis (Wang et al., 2015). Gene expression studies
revealed that ATRmD/mD tumors expressed high levels of “M2” macrophage markers (Arg1,
CD206, PPARG) (Martinez and Gordon, 2014), consistent with the contention that these
infiltrating cells had pro-tumorigenic properties. In contrast, ATRmD/mD tumors exhibited
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the same level of expression of markers known to be associated with “M1” anti-tumor
macrophages (iNOS, TNF-α, IL-6) (Martinez and Gordon, 2014) (Figure 5C,
Supplementary Data File 1 Sheet5). Melanoma cells are known to avoid the immune
response by activating the expression of PD-L1 (Tumeh et al., 2014). ATRmD/mD tumors
expressed higher levels of PD-L1 and lower levels of PD-1 as compared to ATR+/+ tumors
(Figure 5D, Supplemental data file 1-sheet 7), indicating that ATR deficient tumors also
modulated the PD1 immune checkpoint as is observed in human melanomas.

Discussion
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Author Manuscript

Interactions between melanoma cells and immune cells are critical in promoting tumor
initiation, tumor angiotropism (Bald et al., 2014), and therapy resistance (Holzel et al.,
2013). Cancer cells express PD-L1 and CTLA4, which prevents the immune system from
recognizing and destroying tumor cells (Munn and Bronte, 2015), and PD-1 and CTLA4
blocking antibodies can activate the anti-tumor response, leading to tumor regression
(Larkin et al., 2015; Yang, 2015). Existing mouse melanoma models either generate clonal
tumors with little diversity or examine the immune response in syngeneic models that poorly
mimic human disease (Merlino et al., 2013). The autochthonous mouse melanoma model
established here has an intact immune system and generates tumors with mutations in tumor
drivers, tumor suppressors, as well as defects in DNA repair. The observation that M2
macrophages promote tumor growth in this model are consistent with clinical observations
that melanomas with more tumor-infiltrating, M2-like macrophages have a poorer prognosis
(Bronkhorst et al., 2011), and other observations that macrophages promote melanoma
metastasis (Wang et al., 2015). Interestingly, ATR mosaic, p53 null mice also had an
increased number of macrophages localized around the hair follicle (Ruzankina et al., 2009),
indicating that ATR deletion modulates macrophage function. Tumors from ATR mt mice
also overexpress PD-L1, similar to what has been observed in human melanoma tumors that
respond to PD1 inhibitors (Tumeh et al., 2014). In addition, ATR mt tumors downregulate
the expression of butyrophilins (Abeler-Dorner et al., 2012), which normally promote T cell
homing to epithelia (Barbee et al., 2011).

Author Manuscript

Recent studies have highlighted that tumors that have a higher mutation load are more
responsive to immunotherapies (Snyder et al., 2014; Van Allen et al., 2015). While some
studies have suggested that this is the result of generating more tumor neo-antigens, it is
currently unclear why a tumor that expresses a high load of neoantigens would be resistant
to immunotherapy in the first place. The studies presented here identify mutations within
tumor cells themselves that allow them to suppress the T cell immune response and recruit
macrophages known to promote tumor growth. The mouse model described here is an ideal
system to elucidate how melanoma tumors modulate the immune response in order to
develop better immunotherapies.

Experimental Procedures
Mouse breeding, activation of Tyrosinase::CreERT2 transgene, and experimental endpoints

Atrflox, Tyrosinase::CreERT2, BrafCa, and Ptenlox4-5 mice were genotyped using established
protocols. 3μl of a 25 mg/ml solution of 4-OHT (98% Z-isomer, Sigma-Aldrich, St. Louis,
Cell Rep. Author manuscript; available in PMC 2018 March 07.
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MO, USA) in DMSO was applied to the right flank, back skin and tail of mice on postnatal
days 2, 3 and 4. Institutional Animal Care and Use Committee (IACUC) of the University of
California Irvine approved our study protocols. The decision to euthanize mice was
determined by independent University Lab Animal Resource (ULAR) staffs that were
blinded with respect to the mouse genotype. Mice were euthanized if the volume of their
tumors exceeded 10% of total body volume, if tumors were significantly ulcerated, if mice
were moribund, if they lost weight, if they were lethargic, or if they were unable to
ambulate.
Multiphoton microscopy of mouse skin

Author Manuscript

Experimental mice were shave depilated at p50 (second telogen), euthanized, and
immediately imaged ex-vivo (no labeling) with multiphoton microscopy (MPM) to capture
the fluorescence signal from keratin and melanins and second harmonic generated (SHG)
signal from collagen using LSM 510 NLO Zeiss system. Fluorescence and second harmonic
generation was excited by femtosecond Titanium: Sapphire (Chameleon-Ultra, Coherent)
laser at 900 nm. Emission was detected at 390–465 nm for SHG channel (blue), and 500–
550 nm (green) and 565–650 (red) fluorescence channels. Each animal was imaged at 8 to
10 randomly chosen locations on depilated skin of the lower back. Stacks of optical sections
of 636μmx636μm at different depths ranging from 0 to 240 μm (5 μm steps) were obtained
to allow for 3-D volume reconstruction (LSM Image Browser, Carl Zeiss GMBH).
Cell Culture and UVB irradition
For details, see Supplemental Experimental Procedures.
Western blotting of cell lines and mouse tumors and antibodies
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For details, see Supplemental Experimental Procedures.
Expression of ATR wt and mt constructs in A375 melanoma cells
pcDNA3-ATR WT expression construct was purchased form Addgene (plasmid #31611).
The ATR mts were generated by site-specific mutagenesis. (Agilent Technologies, Santa
Clara, CA). Plasmids were transfected into A375 cell line by Turbofect transfection reagent
(Thermo Scientific, Waltham, MA). 48hrs after transfection, cells were selected by G418
selection for 7days. Selected cells were either exposed to UV irradiation as indicated or
subjected to immunoprecipitation followed by western blotting as indicated.
EdU labeling and flow cytometry
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Cells were labeled with 10 μM Edu for 1h, then were irradiated with UVB (250J/m2). At 0hr
or 6hr post-UV cells were fixed and stained with Click-iT Plus EdU Alexa Fluor 647 Flow
Cytometry assay kit (Life technology, Grand Island, NY, USA) according to the
manufacture’s protocol. Cells were subjected to Flow Cytometry with an Attune Acoustic
Focusing Cytometer (Life technology, Grand Island, NY, USA) to analyze the EdU positive
cells. The resulting data were analyzed using Acoustic Focusing Cytometer software (Life
technology, Grand Island, NY, USA).
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For details, see Supplemental Experimental Procedures.
CD3, CD19and F4/80 flow cytometry analysis

Author Manuscript

End stage of mouse tumors were obtained from BRAFV600E PTEN+/− ATRmD/mD, or
BRAFV600E PTEN+/− ATR+/+. Tumors were surgically excised, washed with 70% ethanol
and PBS. Tumors were minced with a scalpel and dissociated using a tumor dissociation kit
(#130-096-730) and gentleMACs (Miltenyi Biotec, Auburn, CA) according to the
manufacture’s protocol. Dissociated tumor cells were labeled by CD3 (17A2)-PE/Cy7,
CD19(6D5)-APC and F4/80 (BM8)-APC/Cy7 (BioLegend, San Diego, CA). Cells were
subjected to flow cytometry using an Attune Acoustic Focusing Cytometer (Life technology,
Grand Island, NY) to analyze the CD3, CD19 and F4/80 positive cells. The resulting data
were analyzed using Acoustic Focusing Cytometer software (Life technology, Grand Island,
NY, USA).
RAW264.7 culture and cytokine stimulation. And mRNA preparation, reverse transcription,
and real-time PCR
For details, see Supplemental Experimental Procedures.
Statistical analysis

Author Manuscript

Kaplan Meier survival curves were generated and significance was assessed using the logrank test, an unpaired t-test, or a two way ANOVA test. Volume of pigmented lesions from
MPM images were measured manually on orthogonal projections to access length, width
and depth of a nevus as it is outlined by a bright luminescence from melanin. Four animals
per group (wt vs mD/mD) were imaged. Other data was analyzed by GraphPad Prism6
statistical analysis software using an unpaired t-test or two way Anova test. Significances
were as indicated.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Author Manuscript

We thank Marcus Bosenberg, Martin McMahon, and Eric Brown for providing us the BRAF mutant and ATR
mutant mice necessary to generate our tumor model. We thank Raymond Zhou, Amy Hopkin, Katerina Yale, and
Vikram Ganesan for technical assistance and Bogi Andersen, Marian Waterman, and Eric Pearlman for reviewing
the manuscript. This work was supported by grants from NIH (1R01CA151513-01 to AKG) and (1R01AR063116
to AKG), NSF (DGE-1321846 to RRV), the Ford Foundation (RRV), and the Stanley Behrens Fellowship (RRV).
The multiphoton microscopy studies were supported by award P41EB015890 from NIBIB (BJT and TBK), and the
genomic studies by P30CA062203 from NCI (JW).

References
Abeler-Dorner L, Swamy M, Williams G, Hayday AC, Bas A. Butyrophilins: an emerging family of
immune regulators. Trends Immunol. 2012; 33:34–41. [PubMed: 22030238]
Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van
den Boorn-Konijnenberg D, Homig-Holzel C, et al. Ultraviolet-radiation-induced inflammation

Cell Rep. Author manuscript; available in PMC 2018 March 07.

Chen et al.

Page 11

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

promotes angiotropism and metastasis in melanoma. Nature. 2014; 507:109–113. [PubMed:
24572365]
Balu M, Kelly KM, Zachary CB, Harris RM, Krasieva TB, Konig K, Durkin AJ, Tromberg BJ.
Distinguishing between benign and malignant melanocytic nevi by in vivo multiphoton microscopy.
Cancer Res. 2014; 74:2688–2697. [PubMed: 24686168]
Barbee SD, Woodward MJ, Turchinovich G, Mention JJ, Lewis JM, Boyden LM, Lifton RP, Tigelaar
R, Hayday AC. Skint-1 is a highly specific, unique selecting component for epidermal T cells. Proc
Natl Acad Sci U S A. 2011; 108:3330–3335. [PubMed: 21300860]
Bauer K, Michel S, Reuschenbach M, Nelius N, von Knebel Doeberitz M, Kloor M. Dendritic cell and
macrophage infiltration in microsatellite-unstable and microsatellite-stable colorectal cancer. Fam
Cancer. 2011; 10:557–565. [PubMed: 21598004]
Box NF, Terzian T. The role of p53 in pigmentation, tanning and melanoma. Pigment Cell Melanoma
Res. 2008; 21:525–533. [PubMed: 18761658]
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP, Jager MJ. Detection of M2macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011;
52:643–650. [PubMed: 20811059]
Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic
lethality. Genes Dev. 2000; 14:397–402. [PubMed: 10691732]
Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome
maintenance. Genes Dev. 2003; 17:615–628. [PubMed: 12629044]
Carson C, Omolo B, Chu H, Zhou Y, Sambade MJ, Peters EC, Tompkins P, Simpson DA, Thomas NE,
Fan C, et al. A prognostic signature of defective p53-dependent G1 checkpoint function in
melanoma cell lines. Pigment Cell Melanoma Res. 2012; 25:514–526. [PubMed: 22540896]
Cassidy PB, Abdel-Malek ZA, Leachman SA. Beyond Red Hair and Sunburns: Uncovering the
Molecular Mechanisms of MC1R Signaling and Repair of UV-Induced DNA Damage. J Invest
Dermatol. 2015; 135:2918–2921. [PubMed: 26569585]
Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. ATR and H2AX cooperate in
maintaining genome stability under replication stress. J Biol Chem. 2009; 284:5994–6003.
[PubMed: 19049966]
Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol.
2008; 9:616–627. [PubMed: 18594563]
Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science.
2001; 294:1713–1716. [PubMed: 11721054]
Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA,
McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic
melanoma. Nat Genet. 2009; 41:544–552. [PubMed: 19282848]
Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C,
Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell.
2009; 15:294–303. [PubMed: 19345328]
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated
macrophages and neutrophils in cancer. Immunobiology. 2013; 218:1402–1410. [PubMed:
23891329]
Gilad O, Nabet BY, Ragland RL, Schoppy DW, Smith KD, Durham AC, Brown EJ. Combining ATR
suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic
lethality or tumorigenesis in a dosage-dependent manner. Cancer Res. 2010; 70:9693–9702.
[PubMed: 21098704]
Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003; 22:3053–3062. [PubMed:
12789280]
Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li
L, Place C, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251–263.
[PubMed: 22817889]
Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a
cause for therapy resistance? Nat Rev Cancer. 2013; 13:365–376. [PubMed: 23535846]

Cell Rep. Author manuscript; available in PMC 2018 March 07.

Chen et al.

Page 12

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript

Jarrett SG, Wolf Horrell EM, Boulanger MC, D’Orazio JA. Defining the Contribution of MC1R
Physiological Ligands to ATR Phosphorylation at Ser435, a Predictor of DNA Repair in
Melanocytes. J Invest Dermatol. 2015; 135:3086–3095. [PubMed: 26168232]
Jarrett SG, Wolf Horrell EM, Christian PA, Vanover JC, Boulanger MC, Zou Y, D’Orazio JA. PKAmediated phosphorylation of ATR promotes recruitment of XPA to UV-induced DNA damage.
Mol Cell. 2014; 54:999–1011. [PubMed: 24950377]
Kuzu OF, Nguyen FD, Noory MA, Sharma A. Current State of Animal (Mouse) Modeling in
Melanoma Research. Cancer Growth Metastasis. 2015; 8:81–94. [PubMed: 26483610]
Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD. Efficacy and Safety of
Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A
Pooled Analysis of 4 Clinical Trials. JAMA Oncol. 2015; 1:433–440. [PubMed: 26181250]
Marechal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect
Biol. 2013; 5
Martincorena I, Roshan A, Gerstung M, Ellis P, Van Loo P, McLaren S, Wedge DC, Fullam A,
Alexandrov LB, Tubio JM, et al. Tumor evolution. High burden and pervasive positive selection of
somatic mutations in normal human skin. Science. 2015; 348:880–886. [PubMed: 25999502]
Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment.
F1000Prime Rep. 2014; 6:13. [PubMed: 24669294]
Masaki T, Wang Y, DiGiovanna JJ, Khan SG, Raffeld M, Beltaifa S, Hornyak TJ, Darling TN, Lee CC,
Kraemer KH. High frequency of PTEN mutations in nevi and melanomas from xeroderma
pigmentosum patients. Pigment Cell Melanoma Res. 2014; 27:454–464. [PubMed: 24483290]
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn
M. Meeting report: The future of preclinical mouse models in melanoma treatment is now.
Pigment Cell Melanoma Res. 2013; 26:E8–E14. [PubMed: 23531109]
Munn DH, Bronte V. Immune suppressive mechanisms in the tumor microenvironment. Curr Opin
Immunol. 2015; 39:1–6. [PubMed: 26609943]
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol.
2011; 11:723–737. [PubMed: 21997792]
Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. ATR inhibition selectively sensitizes G1
checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A.
2001; 98:9092–9097. [PubMed: 11481475]
O’Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA. A splicing mutation affecting
expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome.
Nat Genet. 2003; 33:497–501. [PubMed: 12640452]
Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. Update in genetic
susceptibility in melanoma. Ann Transl Med. 2015; 3:210. [PubMed: 26488006]
Ruzankina Y, Pinzon-Guzman C, Asare A, Ong T, Pontano L, Cotsarelis G, Zediak VP, Velez M,
Bhandoola A, Brown EJ. Deletion of the developmentally essential gene ATR in adult mice leads
to age-related phenotypes and stem cell loss. Cell Stem Cell. 2007; 1:113–126. [PubMed:
18371340]
Ruzankina Y, Schoppy DW, Asare A, Clark CE, Vonderheide RH, Brown EJ. Tissue regenerative
delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nat Genet.
2009; 41:1144–1149. [PubMed: 19718024]
Smith J, Larue L, Gillespie DA. Chk1 is essential for the development of murine epidermal
melanocytes. Pigment Cell Melanoma Res. 2013; 26:580–585. [PubMed: 23557358]
Smits VA, Gillespie DA. DNA damage control: regulation and functions of checkpoint kinase 1. FEBS
J. 2015; 282:3681–3692. [PubMed: 26216057]
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA,
Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N
Engl J Med. 2014; 371:2189–2199. [PubMed: 25409260]
Tanaka A, Weinel S, Nagy N, O’Driscoll M, Lai-Cheong JE, Kulp-Shorten CL, Knable A, Carpenter
G, Fisher SA, Hiragun M, et al. Germline mutation in ATR in autosomal-dominant oropharyngeal
cancer syndrome. Am J Hum Genet. 2012; 90:511–517. [PubMed: 22341969]

Cell Rep. Author manuscript; available in PMC 2018 March 07.

Chen et al.

Page 13

Author Manuscript

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M,
Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune
resistance. Nature. 2014; 515:568–571. [PubMed: 25428505]
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen
MH, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic
melanoma. Science. 2015; 350:207–211. [PubMed: 26359337]
Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. Deciphering AP-1 function in tumorigenesis:
fra-ternizing on target promoters. Cell Cycle. 2007; 6:2633–2639. [PubMed: 17957143]
Wang T, Xiao M, Ge Y, Krepler C, Belser E, Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, et al.
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clin
Cancer Res. 2015; 21:1652–1664. [PubMed: 25617424]
Wellbrock C, Arozarena I. The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of
Melanoma Skin Cancer. Front Cell Dev Biol. 2016; 4:33. [PubMed: 27200346]
Yang Y. Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest. 2015;
125:3335–3337. [PubMed: 26325031]

Author Manuscript
Author Manuscript
Author Manuscript
Cell Rep. Author manuscript; available in PMC 2018 March 07.

Chen et al.

Page 14

Author Manuscript

HIGHLIGHTS
•

Loss of function mutations in ATR are present in human melanoma tumors.

•

ATR mutant nevi and melanomas grow larger than tumors that have
functional ATR.

•

ATR mutant tumors recruit pro-tumorigenic macrophages and block T cell
recruitment.

•

ATR mutations accelerate tumor growth by modulating the tumor
microenvironment.
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Figure 1. Loss of function ATR mutations are present in human melanoma
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(A) ATR mts have a defective DNA damage checkpoints. ATR WT melanoma cell
cultures were irradiated with UVB followed by western blotting with the indicated
antibodies (Ab) (left panel). Relative protein accumulation was measured by densitometry
(see values) relative to a GAPDH loading control. (B) ATR mutations do not accelerate
the rate of proliferation of ATR mt human tumor cells. ATR WT or mts cells were
labeled with EdU and the fraction of proliferating cells was determined. The graph
represents the results of three independent experiments and error bars correspond to SEM. *
p<0.05, **p<0.01; ***p<0.005 (C) ATR mts cells are more sensitive to UV-induced cell
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cycle arrest. ATR WT or mt cells were labeled with EdU for 1hr, irradiated with UVB, and
the fraction of EdU+ cells was determined 0 and 6 hr post-UV as described. * p<0.05,
**p<0.01 (D) Expression of ATR mts in A375 cells impaired the normal DNA damage
response. A375 cells expressing either ATR FLAG tagged WT or mt constructs were lysed
and immunoprecipitation with a FLAG antibody (M2) followed by western blotting with an
ATR Ab to verify that each mt was expressed (left top panel). Total lysate from each culture
expressing ATR WT or mt constructs was also immunoblotted with the indicated antibodies
and relative accumulation of pChk1/Chk1 and pChk1/GAPDH was determined by
densitometry. See also Figure S1 and Table S1A, B.
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Figure 2. ATR haploinsufficiency promotes the invasion and metastasis of BRAF mt melanomas
in mice

(A) Mice carrying various conditional alleles of Braf (BrafCA) , Pten (Ptenlox4-5) and/or ATR
(ATRflox) were crossed to Tyr::CreER mice with melanocyte-specific expression Cre
recombinase (CreERT2). Activation of CreER by 4-OHT leads to melanocyte-specific
conversion of BrafCA to BrafV600E, Pten to null alleles and ATRflox to ATRmD. (B)
Schematic of the ATRflox region (Brown and Baltimore, 2003). The kinase domain-encoding
exons (KD1 and KD2) and primer locations were indicated (top panel). RT-PCR results are
shown in the bottom panel. ATRmD/mD tumors expressed the floxed transcript. (C)
Cell Rep. Author manuscript; available in PMC 2018 March 07.
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ATRmD/mD melanoma cells have defects in ATR signaling. Lysates from mouse tumors
were subjected to western blotting with the indicated specific antibodies. Relative
densitometry values are shown below each blot. n.d. means non-detectable. (D) ATR
haploinsufficiency promotes the growth of BRAFV600E PTEN+/− tumors. The mean
tumor volume of ATR+/+, ATRmD/+, and ATRmD/mD tumors was 91.23+22.68 mm3 (n=28),
428.6+57.95 mm3 (n=28) (p<0.0001), and 495.4+145.8 mm3 (n=27) (p=0.0074),
respectively. Error bars represent SEM. Representative photographs are shown (top panel).
(E) ATR haploinsufficiency accelerates the demise of mice harboring BRAFV600E
PTEN+/− tumors. Kaplan Meier survival curves for mice harboring BRAFV600E PTEN+/−
with ATR+/+, ATRmD/+, and ATRmD/mD tumors with median lifespan 109 days (n=20), 95
days (n=25), and 97 days (n=11), respectively. (F) ATR haploinsufficiency does not
accelerate the demise of mice harboring BRAFV600E PTEN−/− tumors. Kaplan Meier
survival curves for mice harboring BRAFV600E PTEN−/− with ATR+/+, ATRmD/+, and
ATRmD/mD tumors with median lifespan 39 days (n=13), 37 days (n=23), and 40.5 days
(n=12), respectively. (G) ATR haploinsufficiency promotes the metastasis BRAFV600E
PTEN−/− tumors. Mice bearing ATR+/+, ATRmD/+, and ATRmD/mD tumors averaged
1.22+0.43 (n=9), 6.60+0.75 (n=15) and 7.00+0.62 (n=7) metastases per mouse lung
(p<0.0001), respectively. Error bars represent SEM. See also Figure S2 and Table S2.
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Figure 3. ATR mt promotes the growth of BRAF mt nevi and melanomas
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(A) ATR mt promotes the growth of developing melanoma tumors. Tumors were
induced in BrafCA/+ Ptenfl/+ Atrfl/+ or BrafCA/+ Ptenfl/+ Atrfl/fl mice and the size (bottom left
panel) and number of tumors per mouse (bottom right panel) was determined after 75 days.
Mice bearing ATR+/+ tumors had an average of 1.38+0.42 (n=8) tumors per mouse with a
mean volume of 6.06+2.31 mm3 (n=13). Mice bearing ATRmD/+ tumors had an average of
3.9 +0.64 (n=10) tumors per mouse (p=0.0067) with a mean volume of volume of
70.69+19.42 mm3 (n=19), (p<0.0001). ATRmD/mD mice had an average of 3.33+0.88 (n=4),
(p=0.048) with a mean volume of 74.69+22.77 mm3 (n=10), (p<0.0001). Error bars
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represent SEM. (B) ATR mutation promotes the growth of BRAF mt nevi. Nevi were
induced in BrafCA/+ Atr+/+ and BrafCA/+ Atrfl/fl mice and visualized 50 days after induction
on the underside of the skin by standard photography. Mice bearing ATRmD/mD and ATR+/+
nevi had an average of 259.8 +11.72 (n=4), and 74.75+27.69 (n=4) nevi per mouse,
respectively. (p=0.0008). Error bars represent SEM. (C) ATR mt and ATR wt nevi
visualized by label-free multiphoton microscopy of the mouse skin ex-vivo. MPM
images from mice were obtained as described in methods, and a representative image from
each genotype is shown. Top row (left to right): 3-D projections for normal skin, ATR wt
and ATRmD/mD. Bottom row: orthogonal projection from the stacks of images. Colored lines
indicate positions being displayed as xy (blue), xz (red) and yz (green) planes. FOV is
636μm x 636μm Cyan: SHG of collagen; Green: fluorescence of keratin; Yellow and Red –
fluorescence of melanin. (D) ATR mt nevi are larger than ATR wt nevi. Average volume
of melanocytic nevi within the upper 50 μm of the skin was measured (μm3) from 3-D skin
reconstructions. (E) ATR mt nevi occupy a greater volume of the skin as compared to
ATR wt nevi. Percentage of a volume occupied by pigmented lesions within the upper 50
μm of the skin compared to the total probed volume is reported and error bars represent S.D.
(F) ATR mt promote the formation of BRAF mt nevi. Individual lesions were counted
manually for all acquired stacks of images to the depth of 240 μm and then normalized to the
volume of 10 stacks per each animal. A graph obtained from analyzing 5 mice in each group
is shown.
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Figure 4. ATR mt Leads to the Generation of a Genetically Heterogeneous Tumor
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(A) ATR mt leads to the increased accumulation of single nucleotide variants in
melanoma tumors. SNVs that were unique to ATRmD/mD tumors (not present in ATR+/+
tumors) were identified as described in methods. The number of ATR-dependent SNVs (as
defined in the methods section) at each chromosomal location is reported in the graph. mD
denotes ATR mt tumor and WT denotes ATR WT tumors. (B) ATR mt does not lead to the
increased accumulation of specific transitions or transversions. The number of specific
transitions and transversions that were unique to ATRmD/mD tumors was determined, and the
relative proportion of each transition/transversion (proportion of total) is indicated. (C)
Mutation frequencies in ATR mt Tumors. The frequencies of single nucleotide variants in
ATR mt tumors were determined as described in methods. The number of coding and noncoding variants as well as the number of synonymous and non-synonymous variants was
reported for each ATR mt tumor (mD1-mD4). See also Figure S3.
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Figure 5. ATR mt tumors contain a greater number of infiltrating macrophages
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(A) ATR mt nevi modulate the immune response. RNA-sequencing and gene expression
analysis was performed on ATR WT and ATR mt mouse nevi as described. Differentially
expressed genes that regulate proliferation and the immune response identified in the dataset
are shown here, while a larger heatmap (Figure S5A) and dataset is provided in the
supplement (Supplemental data file 1 sheet3). Hierarchical clustering of RNA-seq
normalized read counts obtained from EdgeR ranging from less frequently expressed (dark
blue) to highly (dark red) genes is shown. (B) ATR mt tumors recruit macrophages to
create a pro-inflammatory tumor microenvironment. ATR wt and mt tumor cells were
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labeled by CD3 (T cell marker), CD19 (B cell marker) and F4/80 (macrophage marker)
antibodies and sorted by flow cytometry as described in the supplement. * p<0.05,
***p<0.001. 5 tumors were analyzed per group. Error bars represent SEM. (C) ATR mt
tumors are enriched in M2 like macrophages. RNA samples from ATR wt or mt tumors
were subjected to RT-qPCR. The top panel represents of M1 macrophage expression of
iNOS, TNFα and IL-6. The bottom panel represents of M2 macrophage expression of
ARG1, CD206 and PPARG. (D) ATR mt tumors express more PD-L1. RNA samples from
ATR wt or ATR mt tumors were subjected to RT-qPCR using primers specific for PD-1 or
PD-L1. ***p<0.001, ****p<0.0001, error bars represent SEM. See also Figure S4, S5, S6
and Table S2
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